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TAVI pseudoaneurysm formation (PAF) is a frequent minor vascular
complication. The aim of the study was to compare the incidence of
post-TAVI PAF between the CoreValve (CV) using the St.Jude 18-F-
sheath, the Edwards Sapien XT valve (ESV-XT) using the 16-20 F
Esheath and the Edwards Sapien 3 (EDV-3) with the 14-16 f sheath.
METHODS Between April 2010 and October 2013, 574 pts (age 81.6 
0.41years) with high surgical risk (Euroscore 18.5 0.86%) underwent
successfully TAVI in local anesthesia using either the CV
(23,26,29,31mm), the ESVXT (23, 26, 29mm) or the ESV3 (23, 26,
29mm). Closure of the access site was performed in all pts by using the
ProStar XL 10 suture device. All TAVI pts (361 CV, 106 ESV-XT and 107
ESV-3) were examined serially the ﬁrst 5 days (day 1-3 and 5 post-
TAVI) after the procedure by ultrasound (US) for clinically silent
vascular complications. In case of PAF, ultrasound-guided manual
compression was done followed by compression bandage for another
24 h.
RESULTS In 34 pts (5.9%) we observed major vascular complication
after TAVI (17 [4.7 %] after CV, 7 [6.6%] after ESV-XT and 10 [9.3%]
after ESV-3, p¼0.076). In 123 pts (21.4%) we observed post-TAVI PAF,
which occurred signiﬁcantly more frequently after implantation of the
ESV-XT and ESV-3 than after implantation of the CV. CV versus ESV-
XT versus ESV-3 (60/361 [16.6%] versus 32/106 [30.2%] versus 31/107
[28.9%], p1¼0.01, p2¼0.002 and p3¼0.001). However in total only 8/
123 (6.1 %) patients with PAFs had to be treated surgically, the others
were treated either by ultrasound guided manual compression or
conservatively if smaller than 1 cm.
CONCLUSIONS Clinically silent PAF detected by routine US is a
frequent post-TAVI minor vascular complication which is more likely
to occur after ESV-XT and ESV-3 using the Esheath than after CV.
Although US-guided compression is highly effective, further minia-
turisation of TAVI devices and modiﬁcation of the Esheath design
might help to eliminate post-TAVI PAF.
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BACKGROUND The signiﬁcance of aortic regurgitation (AR) pre-
transcatheter aortic valve implantation (TAVI) implantation is un-
known. The present study aimed to assess the clinical repercussion of
AR in patients undergoing TAVI.
METHODS Retrospective analysis of 150 patients (mean age 817
years old, 43% male), from a tertiary centre prospective registry of 185
consecutive TAVI procedures, between November 2008 and
November 2014. The indication for TAVI was, aortic stenosis in 145
pts, degenerated biologic prosthetic valve in 3 pts and homograft
dysfunction in 2 pts. AR was found in 122 (75%) pts and was moderate
to severe in 33 (22%). We evaluated the clinical differences ate the
presentation and at a median follow up of 22 IQ [2-38] months,
stratiﬁed by the presence of moderate to severe AR, using the
following tests: Qui2, t-student and Mann- Withney.
RESULTS Patients with moderate to severe AR presented more
frequently with a NYHA functional class IV (21% vs 8.5%, p¼0.04) and
with a higher median NT-ProBNP (5190 IQ [1041-11457]pg/ml vs 1765
[795-3632] pg/ml, p¼0.02). During the follow up, they showed a greater
decrease of NT-proBNP (3295 IQ [1082-9621]pg/ml vs 1329 [267-2018]
pg/ml, p¼0.004) and a higher incidence of moderate to severe leak
(24% vs 8%, p ¼ 0.02). The incidence of leak in the overall population
was 65%, being moderate to severe in 16 pts (11%). In pts with leak, the
presence of pre-TAVI moderate to severe AR was associated with a
higher baseline NYHA functional class (p¼0.03) and with a more sig-
niﬁcant functional improvement (> 2 NYHA stages) during the follow
up (p¼0.04). The presence of AR was not associated with 30-day and 1-
year mortality. Seven pts with moderate to severe AR developed
moderate to severe leak. There was no differences between these pts
and the overall population, in what concerns to functional class, NT-
proBNP and cardiovascular events during the follow up.CONCLUSIONS Patients with moderate to severe aortic regurgitation
have a worse baseline clinical status and improve more signiﬁcantly
after transcatheter aortic valve implantation. The presence of AR was
associated with higher incidence of moderate to severe leak without
signiﬁcant clinical repercussion.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
TCT-642
Akute kidney injury (AKI) and chronic kidney injury (CKI) and its relation to
clinical outcome in patients undergoing TAVI
Suzanne Fateh-Moghadam,1 Patrik Htun,2 Tobias Geisler,3
Meinrad Gawaz,4 Wolfgang Bocksch5
1UC Tuebingen, Tuebingen, Germany; 2Zentralklinikum Augsburg,
Augsburg, Germany; 3University Hospital Tübingen, Dept. Cardiology,
Tübingen, Germany; 4University Hospital Tübingen, Department of
Cardiology, Quebec City, BW; 5Eberhard-karls-Universität Tübingen,
Tubingen, Germany
BACKGROUND Transcatheter aortic valve implantation (TAVI) is the
treatment of choice for patients (pts) with severe symptomatic aortic
stenosis (AS) with high surgical risk. Many of these pts present with
chronic renal failure (CRF) or end-stage renal disease (ESRD). Chronic
and acute kidney injury might affect survival after TAVI though cur-
rent data is inconsistent. The aim of this study was to evaluate acute
kidney injury (AKI III) after TAVI under local anesthesia using either
the self-expandable 18-F-CoreValve prosthesis (MCV) or the 14-20F-
balloon expandable Edwards Sapien XT/3 prosthesis (ESV) in relation
to the pre-existent renal function and its association to clinical
outcome.
METHODS Between April 2010 and October 2014, 572 consecutive pts
(age 81.0  0.3years, 281 female) underwent successfully transfemoral
TAVI using either MCV or ESV in local anesthesia exclusively without
general anesthesia or deep sedation. Clinical events and acute kidney
injury (AKI) were evaluated according to the VARC-II criteria.
RESULTS Patients: 334 (58.4%) pts presented with NRF, 221 (38.6 %)
patients with CRF and 17 (2.97 %) pts with end-stage renal disease.
AKI III was 10.6 times higher in the CRF group than in the NRF
group: NRF vs CRF: 0.3% vs 3.2%, p> 0.01. 30-day clinical outcome:
30 day all-cause mortality differed signiﬁcantly between pts with
NRF and CRF and was highest in the ESRD group. NRF: 2.7%; CRF:
5.0%; ESRD: 23.5%). 30 day stroke rate was not signiﬁcantly
enhanced in pts with CRF or ESRD compared to pts with NRF. ( NRF
2.1 % ; CRF 2.3 % ; ESRD 0 %). Long-term clinical outcome: Longterm
mortality differed also signiﬁcantly beween the three groups: NRF
15.3 %; CRF 28.3 %; ESRD 58.8%). In contrast to 30 day-stroke rate,
long-term stroke was highest in the ESRD group. NRF 8.1 %; CRF 5.9
%; ESRD 17.6%. A multivariate analysis including atrial ﬁbrillation,
log Euroscore, age, sex, ejection fraction, type of valve (MCV or
ESV), AKN III and CRF, showed that only CRF represents an inde-
pendent predictor for 30 day mortality.
CONCLUSIONS Chronic and acute kidney injury is associated with
higher 30-day and longterm mortality, being highest in pts with ESRD.
TAVi should be indicated cautiously in patients with ESRD.
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BACKGROUND Due to a different design of the Cobalt chromium alloy
frame, the additional outerskirt to minimize paravalvular leakage and
the thinner struts of the stent frame, one might imagine that the
extent of platelet activation (PA) of the new Edwards Sapien 3 valve
(ESV3) might differ from the Edward Sapien XT valve (ESVXT).
Furthermore paravalvular leaks and hence residual aortic regurgita-
tion should be substantionally reduced The aim of our study was to
compare platelet aggregation (Agg) and platelet activation (PA)
observed with two different catheter valves, the ESV-XT and the
